T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
B-Cell Non-Hodgkin's Lymphoma (NHL) · Lymphoma, Non-Hodgkins · Lymphomas Non-Hodgkin's B-Cell · Non-Hodgkin Lymphoma · Non-Hodgkin's Lymphoma · Large B-Cell Lymphoma · Lymphoma, Non-Hodgkin's, Adult · Lymphoma · Refractory Non-Hodgkin Lymphoma · Relapsed Non-Hodgkin Lymphoma · Lymphoma, Non-Hodgkin · HIV Associated Lymphoma · CNS Lymphoma · High-grade B-cell Lymphoma · Refractory B-Cell Non-Hodgkin Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +13.7
A key executive is leaving
Since Oct 29, 2026 · was worth 15, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 27 (planned)
- Started
- Jun 1, 2024
- Main results expected
- Jul 31, 2027
- Fully finished
- Jul 31, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To assess the safety and tolerability of EB103.
Measured over: Up to 2 years (active assessment period); additional long-term follow-up (LTFU) up to 15 years
To determine the Recommended Phase II Dose (RP2D) of EB103 (in Phase 1, Dose Escalation)
Measured over: Time Frame: 16 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 13.7, since 2026-10-29, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT06343311 · record last updated 2026-10-01 · checked 2026-11-09 15:47 UTC